Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mark Lackner Insider Profile
4 Followers
Mark Lackner, SVP, Head of Biology at IDEAYA Biosciences, holds 195.73K shares in Zentalis Pharmaceuticals (Ticker: ZNTL), holds 0.00 shares in IDEAYA Biosciences (Ticker: IDYA).
Mark Lackner has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Mark Lackner holds in companies
Most Profitable Insider Trade
The most profitable trade made by Mark Lackner
Mark Lackner's Trading History
IDEAYA Biosciences
Jan 28, 2021
SVP, Head of Biology
Uninformative Buy
9.58K
$0.00
Zentalis Pharmaceuticals
Feb 05, 2024
CSO
Uninformative Buy
―
$632.20K
List of latest transactions for each holding click on a transaction to see Mark Lackner's performance on stock
You May Also Like
Mark Lackner insider profile FAQ
What is the percentage of profitable transactions made by Mark Lackner?
The percentage of profitable transactions made by Mark Lackner is ―.
What is the average return per transaction made by Mark Lackner?
The average return per transaction made by Mark Lackner is ―.
What stocks does Mark Lackner hold?
Mark Lackner holds: IDYA, ZNTL stocks.
What was Mark Lackner’s latest transaction?
Mark Lackner latest transaction was an Uninformative Buy of ―.
What was Mark Lackner's most profitable transaction?
Mark Lackner’s most profitable transaction was an Informative Sell of ZNTL stock on February 5, 2024. The return on the trade was 65.10%.
What is Mark Lackner's role in IDEAYA Biosciences?
Mark Lackner's role in IDEAYA Biosciences is SVP, Head of Biology.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.